ArticleFrontiers in immunology2026
Neonatal pulmonary vascular remodeling induced by increased blood flow is associated with an antiviral-like immune signature.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Approximately 70% of pediatric pulmonary arterial hypertension (PAH) is associated with congenital heart disease causing increased pulmonary blood flow (IPF). The developing neonatal lung is highly susceptible to hemodynamic stress, yet the direct causal link and mechanisms of neonatal IPF-induced pulmonary vascular remodeling remain poorly understood due to the lack of suitable animal models that recapitulate this critical developmental window. Methods: We established a novel neonatal mouse model of IPF by performing an aortocaval fistula (ACF) on postnatal day 7(P7). Pulmonary hemodynamics were assessed by ultrasound at P30. Vascular remodeling was evaluated through histology (H&E, α-SMA immunofluorescence) and molecular analysis of phenotypic markers (Spp1, Myh11). Transcriptomic profiling (RNA-seq) and pathway enrichment analysis were employed to uncover underlying mechanisms, with flow cytometry and immunosuppression (Cyclosporin A) and type I interferon receptor blocker (MAR1-5A3) used for functional validation. Results: The neonatal ACF model successfully induced a left-to-right shunt, resulting in significant IPF and right ventricular volume overload. IPF mice exhibited pronounced pulmonary small vessel remodeling, evidenced by increased α-SMA intensity, elevated synthetic-phenotype marker (Spp1) expression, and decreased contractile-phenotype marker (Myh11). Transcriptomic analysis revealed a dominant immune signature, with the most enriched pathways being antiviral and interferon-response related (response to virus and IL-17 signaling). This was corroborated by a significant increase in pulmonary CD4+ and CD8+ T cells. Crucially, immunosuppressive treatment and type I interferon receptor blocker attenuated vascular remodeling. Conclusions: We provide the direct experimental evidence that neonatal IPF alone is sufficient to drive pulmonary small vessel remodeling. The process is fundamentally mediated by an activated immune response characterized by an antiviral-like signature, a mechanism distinct from those reported in classic adult PAH models. This novel model offers a critical platform for investigating the developmental-specific pathogenesis of pediatric PAH and bridging the translational "valley of death."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.